Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. a comparatively little subset of sufferers is triple detrimental for mutations in every three genes (10C20%) [6C9]. Ruxolitinib can be a JAK1/JAK2 inhibitor authorized by the united states Food and Medication Administration for individuals with intermediate- … [Read more…]